Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

被引:0
作者
S M A Kazmi
R M Saliba
M Donato
M Wang
C Hosing
S Qureshi
P Anderlini
U Popat
R E Champlin
S A Giralt
M H Qazilbash
机构
[1] University of Texas Health Science Center at Houston,Department of Internal Medicine
[2] University of Texas MD Anderson Cancer Center,Department of Stem Cell Transplantation and Cellular Therapy
[3] University of Texas MD Anderson Cancer Center,Department of Lymphoma and Myeloma
来源
Bone Marrow Transplantation | 2011年 / 46卷
关键词
topotecan; melphalan; CY; multiple myeloma; autologous stem cell transplant;
D O I
暂无
中图分类号
学科分类号
摘要
In spite of high-dose chemotherapy followed by autologous hematopoietic SCT multiple myeloma (MM) eventually recurs, highlighting the need for more effective treatment approaches. Patients received topotecan 3.5 mg/m2 intravenously on days –6 to –2, melphalan 70 mg/m2 intravenously on days –3 and –2 and CY 1 g/m2 intravenously on days –6, –5 and –4. Overall response rate (ORR) consisting of complete response and partial response (CR+PR, PFS, OS and toxicity are reported. Between August 2002 to March 2004, 60 patients (34 men and 26 women) with a median age of 61 years (range 45–72) were enrolled. Forty-one patients were treated for consolidation of first remission, while 19 patients had relapsed/refractory disease. ORR was 85% (CR 12%, very good PR 43% and PR 30%). Median time to neutrophil (ANC>0.5 × 109/L) and plt engraftment (>20 × 109/L) was 10 (range 7–12 days) and 9 days (range 6–79 days), respectively. A majority of the common adverse events were grade 1–3 mucositis/stomatitis (65%), grade 1 or 2 nausea (59%) and grade 1 or 2 diarrhea (41%). Median PFS was 18.5 months and median OS has yet not been reached. In conclusion, topotecan, melphalan and CY is a safe and active conditioning regimen for auto hematopoietic SCT in MM. The ORR and PFS were comparable to high-dose melphalan.
引用
收藏
页码:510 / 515
页数:5
相关论文
共 50 条
[41]   Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial [J].
Blanes, Margarita ;
de la Rubia, Javier ;
Lahuerta, Juan J. ;
Gonzalez, Jose D. ;
Ribas, Paz ;
Solano, Carlos ;
Alegre, Adrian ;
Sanz, Miguel A. .
LEUKEMIA & LYMPHOMA, 2009, 50 (02) :216-222
[42]   High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan [J].
Nieto, Yago ;
Valdez, Benigno C. ;
Pingali, Sai R. ;
Bassett, Roland ;
Delgado, Ruby ;
Nguyen, John ;
Shah, Nina ;
Popat, Uday ;
Jones, Roy B. ;
Andersson, Borje S. ;
Gulbis, Alison ;
Ahmed, Sairah ;
Bashir, Qaiser ;
Parmar, Simrit ;
Patel, Krina ;
Myers, Alan ;
Rondon, Gabriela ;
Orlowski, Robert Z. ;
Champlin, Richard ;
Qazilbash, Muzaffar .
LANCET HAEMATOLOGY, 2017, 4 (06) :E283-E292
[43]   Multiple myeloma, high-dose treatment and autologous stem cell transplantation - Current status [J].
Bjorkstrand, B .
MEDICAL ONCOLOGY, 1996, 13 (01) :23-30
[44]   High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma [J].
Gertz, Marie A. ;
Lacy, Martha Q. ;
Dispenzieri, Angela ;
Hayman, Suzanne R. ;
Kumar, Shaji K. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (03) :343-360
[45]   A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant [J].
Martino, Massimo ;
Gori, Mercedes ;
Tripepi, Giovanni ;
Recchia, Anna Grazia ;
Cimminiello, Michele ;
Provenzano, Pasquale Fabio ;
Naso, Virginia ;
Ferreri, Anna ;
Moscato, Tiziana ;
Console, Giuseppe ;
Loteta, Barbara ;
Gallo, Giuseppe Alberto ;
Gentile, Massimo ;
Innao, Vanessa ;
Rossi, Marco ;
Morabito, Antonella ;
Vincelli, Iolanda Donatella ;
Mannina, Donato ;
Pitino, Annalisa .
ANNALS OF HEMATOLOGY, 2020, 99 (02) :331-341
[46]   A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant [J].
Massimo Martino ;
Mercedes Gori ;
Giovanni Tripepi ;
Anna Grazia Recchia ;
Michele Cimminiello ;
Pasquale Fabio Provenzano ;
Virginia Naso ;
Anna Ferreri ;
Tiziana Moscato ;
Giuseppe Console ;
Barbara Loteta ;
Giuseppe Alberto Gallo ;
Massimo Gentile ;
Vanessa Innao ;
Marco Rossi ;
Antonella Morabito ;
Iolanda Donatella Vincelli ;
Donato Mannina ;
Annalisa Pitino .
Annals of Hematology, 2020, 99 :331-341
[47]   Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma [J].
Sunami, Kazutaka ;
Shinagawa, Katsuji ;
Sawamura, Morio ;
Sakai, Akira ;
Saburi, Yoshio ;
Imamura, Yutaka ;
Mizuno, Ishikazu ;
Tamaki, Shigehisa ;
Kamimura, Tomohiko ;
Tsuda, Hiroyuki ;
Gondo, Hisashi ;
Hino, Norihiko ;
Shimazaki, Chihiro ;
Miyata, Akira ;
Tajima, Fumihito ;
Takemoto, Yoshinobu ;
Miwa, Akiyoshi ;
Chou, Takaaki ;
Harada, Mine .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (05) :635-642
[48]   Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study [J].
Atsushi Isoda ;
Rie Saito ;
Fuminori Komatsu ;
Yuki Negishi ;
Noriyasu Oosawa ;
Tetsuya Ishikawa ;
Yuri Miyazawa ;
Morio Matsumoto ;
Morio Sawamura ;
Akihiro Manaka .
International Journal of Hematology, 2017, 105 :478-484
[49]   Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy [J].
Bo-Hee Lee ;
Seung Hwan Shin ;
Chang-Ki Min ;
Ho-Young Yhim ;
Jae-Yong Kwak ;
Jeong-A Kim .
International Journal of Hematology, 2013, 97 :634-639
[50]   Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study [J].
Isoda, Atsushi ;
Saito, Rie ;
Komatsu, Fuminori ;
Negishi, Yuki ;
Oosawa, Noriyasu ;
Ishikawa, Tetsuya ;
Miyazawa, Yuri ;
Matsumoto, Morio ;
Sawamura, Morio ;
Manaka, Akihiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (04) :478-484